Herein, we adopted an innovative RNA nanotechnology approach to overcome some of the aforementioned challenges, and report for the first time a new strategy to target and deliver therapeutic BRCAA1 siRNA to in vivo stomach cancer tissues using FA-conjugated pRNA-3WJ nanoparticles. The gene discussed is ARID4B; the disease is gastric cancer.